SB 25-121: Medicaid Reimbursement for Vagus Nerve Stimulation - Colorado

PA1 (02/21/2025) → PA2 (04/22/2025) · 3 edits

MINOR

This bill amendment adjusts the reimbursement schedule for vagus nerve stimulator devices for drug-resistant epilepsy patients. The most significant change is that reimbursement begins at 60% of device cost instead of 75%, with a scheduled increase to 75% starting January 1, 2029, rather than immediately. The amendment also reorganizes the statutory language by adding subsection letters (a) and (b) for better structure.

Scope change

The bill's scope remains the same - it still applies to acute care hospitals and ambulatory surgery facilities providing vagus nerve stimulation therapy to Colorado members with drug-resistant epilepsy - but the financial terms and implementation timeline have been modified.

FISCAL

Initial reimbursement rate changed from 75% to 60% of device cost, reducing immediate financial impact on healthcare providers and state budget.

TIMELINE

Added a phased implementation schedule with reimbursement increasing from 60% to 75% beginning January 1, 2029, providing a transition period.

TECHNICAL

Reorganized statutory language by adding subsection letters (a) and (b) for improved readability and legal structure.

Reengrossed (04/23/2025) → PA1 (02/21/2025) · 4 edits

MODERATE

The bill was amended to increase the reimbursement rate for vagus nerve stimulator devices from 60% to 75% of the device cost, and reorganized the timeline for implementation to occur after federal authorization is received rather than on a fixed date. The changes clarify that reimbursement applies to surgical procedures associated with implanting the device and maintain the safety clause language.

Scope change

The bill's scope remains focused on healthcare reimbursement for drug-resistant epilepsy treatment, but the financial terms and implementation timeline were modified.

FISCAL

Increased reimbursement rate from 60% to 75% of the vagus nerve stimulator device cost.

TIMELINE

Removed fixed implementation dates (January 1, 2026 and January 1, 2029) and replaced with a requirement to implement upon receiving federal authorization.

REQUIREMENT

Added explicit language confirming reimbursement includes necessary surgical procedures for implanting the device.

TECHNICAL

Removed redundant subsections and reorganized the statute structure for clarity.

Engrossed (04/22/2025) → Reengrossed (04/23/2025) · 3 edits · Apr 23, 2025

MINOR

The bill was reengrossed to include additional Senate co-sponsors and updated the bill summary to reflect amendments adopted during the House of Introduction third reading. No substantive policy changes were made to the bill's content, scope, or requirements.

TECHNICAL

Added five new Senate co-sponsors (Amabile, Ball, Coleman, Cutter, Daugherty, Exum, Gonzales J., Kipp, Marchman, Michaelson Jenet, Roberts, Snyder, Sullivan, Wallace) to the bill sponsorship list.

Updated the bill summary header from 'ENGROSSED' to 'REENGROSSED' to reflect that all amendments adopted in the House of Introduction are now included in this version.

Modified the bill summary note to indicate that a new summary will be available after third reading in the House of Introduction, dated April 23, 2025.

Introduced (02/04/2025) → Engrossed (04/22/2025) · 5 edits · Apr 23, 2025

MODERATE

The bill was amended to change the reimbursement rate for vagus nerve stimulator devices from 75% to 60%, delay the start of reimbursement from July 2025 to January 2026, and add a new provision to increase reimbursement to 75% beginning in 2029 upon federal authorization. The Senate Appropriations Committee was added to the committee assignments.

Scope change

The bill's scope was modified to include a phased reimbursement approach with a lower initial rate and a future increase contingent on federal approval.

FISCAL

The reimbursement rate for vagus nerve stimulator devices was reduced from 75% to 60% of the device cost.

TIMELINE

The start date for reimbursement was delayed from July 1, 2025 to January 1, 2026.

A new provision was added to increase reimbursement to 75% beginning January 1, 2029, upon receiving federal authorization.

REQUIREMENT

A new requirement was added for the state department to seek federal authorization before implementing reimbursement.

SCOPE

The Senate Appropriations Committee was added to the bill's committee assignments.

Medicaid Reimbursement for Vagus Nerve Stimulation

What changed between versions

How they voted

Actions timeline

Sponsors